Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | PPARA | Q07869 | 2/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9044977 | 0.88 | MEN1 (0.36) | MEN1KMT2ATDP1SLC6A3ITGB1 | |
| SCHEMBL20764818 | 0.86 | MEN1 (0.34) | MEN1KMT2ATDP1SLC6A3ALDH1A1 | |
| SCHEMBL9787 | 0.86 | MEN1 (0.34) | MEN1KMT2ATDP1SLC6A3ALDH1A1 | |
| SCHEMBL29087904 | 0.85 | MEN1 (0.38) | MEN1KMT2ASLC6A3ITGB1ITGA4 | |
| SCHEMBL30638082 | 0.85 | MEN1 (0.38) | MEN1KMT2ASLC6A3ITGB1ITGA4 | |
| SCHEMBL4100097 | 0.85 | CA2 (0.38) | MEN1KMT2APPARG | |
| SCHEMBL10518210 | 0.83 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL30989292 | 0.83 | MEN1 (0.38) | MEN1KMT2A | |
| SCHEMBL9213202 | 0.81 | MEN1 (0.37) | MEN1KMT2ASLC6A3ALDH1A1 | |
| SCHEMBL9044354 | 0.81 | MEN1 (0.37) | MEN1KMT2ASLC6A3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10085986-B2 | Pyrimidinone compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| EP-2729453-B1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL (JP) | 2015-05-06 | — | — | EP | disclosed |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-04 | — | — | US | disclosed |
| EP-2729453-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | Takeda Pharmaceutical Company Limited (JP) | 2014-05-14 | — | — | EP | disclosed |
| WO-2013004995-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-10 | — | — | WO | disclosed |
| US-8288531-B2 | Preparation process | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| US-20110087021-A1 | NOVEL PREPARATION PROCESS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110087021-A1 | NOVEL PREPARATION PROCESS | CYP2F1, CYP11B2, CYP11B1 | MEN1 270/4885KMT2A 4366/4885TDP1 3653/4885 |
| US-20140248378-A1 | PYRIMIDINONE COMPOUNDS AND THEIR USE | TPMT, DHFR, DPYD | MEN1 735/4885KMT2A 1162/4885TDP1 1216/4885 |
| US-10085986-B2 | Pyrimidinone compounds and their use | TPMT, DHFR, DPYD | MEN1 735/4885KMT2A 1162/4885TDP1 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.